Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (May 2022)
25 slides from Evofem Biosciences's investor presentation, May 26, 2022
Slide 1: The Home of Phexxi
F O R I N V E S T O R D I S C U S S I O N S O N L Y T H E H O M E O F P H E X X I – T H E F I R S T A N D O N L Y F D A - A P P R O V E D O N - D E M A N D , N O N - H O R M O N A L C O N T R A C E P T I V E G E L . S C I E N C E W I T H A S O U L S A U N D R A P E L L E T I E R C H I E F E X E C U
Slide 2: Forward-Looking Statements
F O R I N V E S T O R D I S C U S S I O N S O N L Y FORWARD-LOOKING STATEMENTS Thi s pr es ent at i on cont a i ns f or war d l ook i ng s t at ement s wi t h i n t he meani ng of The Pr i vat e Secur i t i es L i t i gat i on Ref or m Act of 1995 and ot her f eder a l s ecur i t i es l aws . I n s
Slide 3: Nearly half of all pregnancies worldwide are unintended
F O R I N V E S T O R D I S C U S S I O N S O N L Y NEARLY HALF OF ALL PREGNANCIES W ORLDW IDE – ABOUT 121 M ILL ION – ARE UNINTENDED. U N F P A ’ s a n n u a l r e p o r t . 62.9% OF WOMEN WHO STOPPED USING ORAL CONTRACEPTIVES DID SO BECAUSE OF SIDE EFFECTS. 2 0 1 3 N a t i o n a l H e a l t h S t
Slide 4: A new category with no FDA-approved competition
F O R I N V E S T O R D I S C U S S I O N S O N L Y A N E W C A T E G O R Y W I T H N O F D A - A P P R O V E D C O M P E T I T I O N Phexxi is a product creating a brand-new contraception category. Although there are other well-established contraceptive solutions on-market, there’s no solution that
Slide 5: We're leading the revolution
F O R I N V E S T O R D I S C U S S I O N S O N L Y WE’RE LEADING THE REVOLUTION With innovative women’s reproductive and sexual health solutions MULTI-BILLION DOLLAR MARKET OPPORTUNITY FOR CURRENT AND LATE-STAGE INVESTIGATIONAL INDICATIONS THE FIRST AND ONLY ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTI
Slide 6: A new category of birth control
F O R I N V E S T O R D I S C U S S I O N S O N L Y A NEW CATEGORY OF BIRTH CONTROL On-demand, non-hormonal FDA-approved vaginal contraceptive gel T H E F I R S T A N D O N L Y O N - D E M A N D , N O N - H O R M O N A L P R E S C R I P T I O N C O N T R A C E P T I V E V A G I N A L G E L • p H M O
Slide 7: Proven to prevent pregnancies without hormones
F O R I N V E S T O R D I S C U S S I O N S O N L Y PROVEN TO PREVENT PREGNANCIES W/O HORMONES Results of AMPOWER | A phase 3 multicenter, single-arm, open label clinical trial (n=1384) P R I M A R Y E N D P O I N T 86% EFFICACY RATE OVER 7 CYCLES K A P L A N - M E I E R / T I M E - T O - E V E N T
Slide 8: MOA - Phexxi is a pH modulator
F O R I N V E S T O R D I S C U S S I O N S O N L Y MOA - PHEXXI IS A pH MODULATOR Baseline vaginal pH levels can range from 3.5 – 4.5 W H EN SEM EN (p H 7 .1 -8 ) EN TER S TH E V A G IN A , IT R A ISES TH E EN V IR O N M EN TA L p H LEV EL A L L O W S S P E R M T O B E M O B I L E A N D S W I M U P
Slide 9: Potential market opportunity: $1.4 to 2.3B
F O R I N V E S T O R D I S C U S S I O N S O N L Y POTENTIAL MARKET OPPORTUNITY: $1.4 TO 2.3B Based on U.S. contraceptive market breakdown N O N -R X CO N TR A CEP TIV E U S ER S | 1 0 .3 M W O M EN P o t e n t i a l a c q u i s i t i o n 3 . 5 - 4 . 5 % | 3 6 0 - 4 6 0 K u s e r s ( 2 ) | M a r k
Slide 10: Phexxi celebrity campaign
F O R I N V E S T O R D I S C U S S I O N S O N L Y PHEXXI CELEBRITY CAMPAIGN Annie Murphy x Phexxi 10
Slide 11: New publication: sexual satisfaction data
F O R I N V E S T O R D I S C U S S I O N S O N L Y N E W P U B L I C A T I O N : S E X U A L S A T I S F A C T I O N D A T A Exploratory data from AMPOWER | A Phase 3 multicenter, single-arm, open label clinical trial (n=1330) P U B L I S H E D I N T H E P E E R - R E V I E W E D J O U R N A L O F
Slide 12: Vitacare prescription services agreement
F O R I N V E S T O R D I S C U S S I O N S O N L Y VITACARE PRESCRIPTION SERVICES AGREEMENT Enhanced “white glove” patient support • H elp s p at ien t n av igate co verage an d id en t i fy sav in gs o p p o rtu n it ies • Fac i l i ta tes co m m u n icat io n s b etw een h ea l th care p ro v id
Slide 13: Chlamydia & gonorrhea prevention Phase 3 EVOGUARD trial
F O R I N V E S T O R D I S C U S S I O N S O N L Y CHLAMYDIA & GONORRHEA PREVENTION PHASE 3 EVOGUARD TRIAL
Slide 14: Chlamydia & gonorrhea prevention: registrational Phase 3 EVOGUARD trial
F O R I N V E S T O R D I S C U S S I O N S O N L Y CHLAMYDIA & GONORRHEA PREVENTION | REGISTRATIONAL PHASE 3 EVOGUARD TRIAL Near-term significant opportunity CH LA M YD IA IS TH E M O S T F R EQ U EN TLY R EP O R TED B A CTER IA L IN F ECT IO N IN TH E U .S . (1) • I n c i d e n c e : 4 m i l l i o
Slide 15: Chlamydia & gonorrhea prevention: expected timeline
F O R I N V E S T O R D I S C U S S I O N S O N L Y CHLAMYDIA & GONORRHEA PREVENTION | EXPECTED TIMELINE Near-term significant opportunity PHASE 3 EVOGUARD TRIAL (1903 WOMEN, OVER 100 U.S. SITES) FDA HAS GRANTED EVO100 (PHEXXI) FAST TRACK DESIGNATION AND QIDP DESIGNATION FOR THE PREVENTION OF BOTH C
Slide 16: Other growth and value creation opportunities
F O R I N V E S T O R D I S C U S S I O N S O N L Y OTHER GROWTH AND VALUE CREATION OPPORTUNITIES Partnerships and more
Slide 17: Other growth and value creation opportunities
F O R I N V E S T O R D I S C U S S I O N S O N L Y OTHER GROWTH AND VALUE CREATION OPPORTUNITIES Partnerships and more SECU R E P A R TN ER SH IP (S ) FO R CO M M ER CIA L IZA T IO N O F P H EXXI IN FO R EIG N M A R KETS • U p fro n t cap i ta l • M ilesto n e p aym en ts • T iered ro ya l t ies o
Slide 18: Increasing Phexxi net product sales
$1.1 $1.9 $1.7 $3.6 $4.3 $- $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 $3.5 $4.0 $4.5 $5.0 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 INCREASING PHEXXI NET PRODUCT SALES 19% INCREASE F R O M Q 4 2 0 2 1 T O Q 1 2 0 2 2 IN M IL LI O NS 18
Slide 19: Reducing our total operating expenses
$46.0 $43.0 $45.1 $41.0 $33.2 $- $5.0 $10.0 $15.0 $20.0 $25.0 $30.0 $35.0 $40.0 $45.0 $50.0 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 REDUCING OUR TOTAL OPERATING EXPENSES IN M IL LI O NS 19% DECREASE F R O M Q 4 2 0 2 1 T O Q 1 2 0 2 2 19
Slide 20: Improving our loss from operations
$(44.9) $(41.1) $(43.4) $(37.4) $(28.1) $(50.0) $(40.0) $(30.0) $(20.0) $(10.0) $- Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 IMPROVING OUR LOSS FROM OPERATIONS IN M IL LI O NS 20
Slide 21: Manufacturing agreement: Bora Pharmaceuticals Services
F O R I N V E S T O R D I S C U S S I O N S O N L Y MANUFACTURING AGREEMENT: BORA PHARMACEUTICALS SERVICES, INC. CANADA 45% reduction in cost of goods • B o ra h as p ro ven exp ert i se in G M P m an u factu r in g o f d ru g p ro d u cts • Exp ected to d ecrease co st o f go o d s 4 5 % re la ted
Slide 22: Executing on our strategic initiatives: 2022
F O R I N V E S T O R D I S C U S S I O N S O N L Y EXECUTING ON OUR STRATEGIC INITIATIVES: 2022 1 . Exp an d P h exx i access 2 . In crease P h exx i n et reven u es 3 . Fu rth er red u ce o p erat in g exp en ses 4 . R ep o rt EVOGUARD t r ia l to p - l in e resu l ts 5 . A d van ce b u s in ess d
Slide 23: Financial highlights: EVFM
F O R I N V E S T O R D I S C U S S I O N S O N L Y FINANCIAL HIGHLIGHTS: EVFM B A LA N CE S H EET H IG H LIG H TS (as o f M arch 3 1 , 2 0 2 2 ) • $ 2 .8 M cash an d cash eq u iva len ts • $ 4 .2 M restr ic ted cash STR EN G TH EN ED B A LA N CE SH EET IN Q 2 2 0 2 2 • $ 2 6 .6 M in gro ss p ro cee
Slide 24: Shattering the hormone glass ceiling
F O R I N V E S T O R D I S C U S S I O N S O N L Y SHATTERING THE HORMONE GLASS CEILING
Slide 25: Let's talk
F O R I N V E S T O R D I S C U S S I O N S O N L Y L E T ’ S T A L K . IN V ES TO R CO N T A CT: A m y R asko p f , V P o f In vesto r R e lat io n s + 1 9 1 7 6 7 3 5 7 7 5 i r@ evo fem .co m 25
Evofem Biosciences — Investor Presentation (May 2022) on 6ix